Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study

(2020) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial

(2019) Atul Deodhar et al.   LANCET

Epidemiology of axial spondyloarthritis

(2018) Runsheng Wang et al.   CURRENT OPINION IN RHEUMATOLOGY

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

(2018) Désirée van der Heijde et al.   LANCET

Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)

(2018) Mitsumasa Kishimoto et al.   Modern Rheumatology

IL-17A Inhibition Diminishes Inflammation and New Bone Formation In Experimental Spondyloarthritis

(2018) Melissa N. van Tok et al.   Arthritis & Rheumatology

Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor

(2018) Atul Deodhar et al.   Arthritis & Rheumatology

Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies

(2017) James C.-C. Wei et al.   International Journal of Rheumatic Diseases

FRI0428 Epidemiology of Ankylosing Spondylitis in Taiwan: A Nationwide Population Study

(2016) M.-Y. Hsieh et al.   ANNALS OF THE RHEUMATIC DISEASES

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Targeting the interleukin-23/17 axis in axial spondyloarthritis

(2016) Ananta Paine et al.   CURRENT OPINION IN RHEUMATOLOGY

The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis

(2016) Malcolm J Price et al.   HEALTH TECHNOLOGY ASSESSMENT

Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study

(2016) Hidemi Nakagawa et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

(2016) Ajay Nirula et al.   RHEUMATOLOGY

Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis

(2016) Carmen Stolwijk et al.   ARTHRITIS CARE & RESEARCH

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers

(2014) Anja Weiß et al.   ARTHRITIS RESEARCH & THERAPY

Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign

(2012) Aurélia Bisson-Vaivre et al.   JOINT BONE SPINE

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection

(2009) M Rudwaleit et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis

(2009) M. RUDWALEIT et al.   JOURNAL OF RHEUMATOLOGY